{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:30:59Z","timestamp":1787225459776,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Definitive radiotherapy discontinuation is a critical key performance indicator (KPI) in oncological care. This study aimed to determine the frequency of definitive radiotherapy discontinuation and to characterise the clinical profile of a cohort treated between 2020 and 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective descriptive study of 16,292 fractionated radiotherapy courses initiated between January 2020 and December 2024. Definitive discontinuation was defined as the cessation of treatment before completing the planned dose for any reason. We analysed demographic, clinical, and dosimetric variables, and classified the reasons for discontinuation into predefined categories. Statistical analysis included descriptive statistics to characterise the discontinuation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 279 definitive discontinuations (1.71%) were recorded. The mean age was 66.0\u2009\u00b1\u200913.9\u00a0years (60.2% male). The discontinuation rate was significantly higher for palliative than for curative courses (3.49% vs. 1.08%). Causes of discontinuation differed significantly by intent: death from oncological causes predominated in the palliative group (49.0%), whereas non-oncological complications were the leading cause in the curative cohort (33.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Treatment persistence analysis revealed that palliative courses were interrupted significantly earlier in their planned schedule (median completion 50.0%) compared to curative courses (64.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). A compromised performance status (KPS\u2009&lt;\u200970) was present in 29.7% of courses. COVID-19 caused only eight direct discontinuations (2.8%). The 2020 temporal peak (2.45%) was driven almost exclusively by the palliative cohort (5.24%), while curative discontinuation rates remained stable (~\u20091.0%). The discontinued cohort was clinically characterised by advanced age, compromised performance status, metastatic disease, palliative treatment intent, and treatment initiation delays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The definitive discontinuation rate was low compared with previously reported series. Oncological factors were the predominant causes, especially in palliative treatments. Differentiating between unavoidable events (e.g. rapid oncological deterioration) and potentially avoidable ones (e.g. toxicity or patient decision) transforms this metric into a practical quality indicator. Although direct COVID-19 discontinuations were minimal, the pandemic highlighted the vulnerability of palliative pathways during systemic crises. When appropriately stratified and interpreted, this indicator may provide a framework for inter-institutional comparison and benchmarking, supporting targeted quality improvement strategies such as optimisation of patient selection, increased use of hypofractionated regimens in limited-prognosis patients, and enhanced supportive care for high risk and vulnerable subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04519-x","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:18:07Z","timestamp":1787224687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The landscape of definitive radiotherapy discontinuation: a 5-year institutional audit and clinical profiling"],"prefix":"10.1007","author":[{"given":"Javier","family":"Gonz\u00e1lez-Viguera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-3473","authenticated-orcid":false,"given":"M\u00edriam","family":"N\u00fa\u00f1ez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalla","family":"Santa Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Maci\u00e0 i Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Guedea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Eraso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"1","key":"4519_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.radonc.2014.03.024","volume":"112","author":"MB Barton","year":"2014","unstructured":"Barton MB, Jacob S, Shafiq J, et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2003;112(1):140\u20134.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4519_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2016.02.016","volume":"119","author":"JM Borras","year":"2016","unstructured":"Borras JM, Lievens Y, Barton M, et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol. 2025;119(1):5\u201311.","journal-title":"Radiother Oncol"},{"issue":"2","key":"4519_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/02841868809090333","volume":"27","author":"HR Withers","year":"1988","unstructured":"Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131\u201346.","journal-title":"Acta Oncol"},{"key":"4519_CR4","volume-title":"Basic clinical radiobiology","author":"GG Steel","year":"2002","unstructured":"Steel GG. Basic clinical radiobiology. 3rd ed. London: Arnold; 2002.","edition":"3rd ed"},{"issue":"2","key":"4519_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","volume":"23","author":"JF Fowler","year":"1992","unstructured":"Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(2):457\u201367.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4519_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.radonc.2010.03.020","volume":"96","author":"HD Thames","year":"2010","unstructured":"Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol. 1987;96(1):6\u201312.","journal-title":"Radiother Oncol"},{"issue":"1","key":"4519_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4\u201314.","journal-title":"Radiother Oncol"},{"issue":"3","key":"4519_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijrobp.2005.03.037","volume":"63","author":"M Machtay","year":"2005","unstructured":"Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63(3):667\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4519_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ijrobp.2007.03.010","volume":"68","author":"NS Bese","year":"2007","unstructured":"Tyldesley S, Sheehan F, Munk P, et al. The impact of tumor volume and systemic therapy on survival in patients with brain metastases treated with stereotactic radiosurgery. Am J Clin Oncol. 2006;29(4):408\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4519_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/jjco\/hyd059","volume":"30","author":"YP Chen","year":"2000","unstructured":"Chen YP, Tsang NM, Tseng CK, et al. Causes of interruption of radiotherapy in nasopharyngeal carcinoma patients in Taiwan. Jpn J Clin Oncol. 2000;30(5):230\u20134.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"4519_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cam4.114","volume":"2","author":"H Badakhshi","year":"2013","unstructured":"Badakhshi H, Gruen A, Sehouli J, et al. The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study. Cancer Med. 2013;2(5):712\u20137.","journal-title":"Cancer Med"},{"issue":"5","key":"4519_CR12","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1111\/ajco.12572","volume":"13","author":"JA Lee","year":"2017","unstructured":"Lee JA, Lee NK, Yoon WS, et al. Treatment interruption during radiation therapy: experience at a single institution in the Republic of Korea. Asia Pac J Clin Oncol. 2016;12(4):e417\u201324.","journal-title":"Asia Pac J Clin Oncol"},{"key":"4519_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13014-014-0260-0","volume":"9","author":"M Arenas","year":"2014","unstructured":"Arenas M, Sabater S, Gasc\u00f3n M, et al. Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal. Radiat Oncol. 2014;9:260.","journal-title":"Radiat Oncol"},{"issue":"9","key":"4519_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1001\/archoto.2009.108","volume":"135","author":"MD Fesinmeyer","year":"2009","unstructured":"Fesinmeyer MD, Mehta V, Tock L, et al. Completion of radiotherapy for local and regional head and neck cancer in medicare. Arch Otolaryngol Head Neck Surg. 2009;135(9):860\u20137.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"15","key":"4519_CR15","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2011.35.7442","volume":"30","author":"P Soubeyran","year":"2012","unstructured":"Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829\u201334.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4519_CR16","doi-asserted-by":"publisher","first-page":"e782","DOI":"10.1200\/JOP.2017.021220","volume":"13","author":"LL Puckett","year":"2017","unstructured":"Puckett LL, Nunn M, Finlayson C, et al. Preventing discontinuation of radiation therapy: factors associated with discontinuation of palliative radiation therapy. J Oncol Pract. 2017;13(9):e763\u20139. https:\/\/doi.org\/10.1200\/JOP.2016.020297.","journal-title":"J Oncol Pract"},{"issue":"2","key":"4519_CR17","doi-asserted-by":"publisher","first-page":"e000759","DOI":"10.1136\/esmoopen-2020-000759","volume":"5","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Toss A, Passaro A, et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists\u2019 perspective. ESMO Open. 2019;5(2):e000759.","journal-title":"ESMO Open"},{"issue":"3","key":"4519_CR18","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.adro.2021.100680","volume":"6","author":"P Pendyala","year":"2021","unstructured":"Pendyala P, Ai WZ, Maraboyina S, et al. Impact of the coronavirus disease of 2019 pandemic on radiation therapy practices and patient care: a multi-institutional study. Adv Radiat Oncol. 2021;6(2):100639.","journal-title":"Adv Radiat Oncol"},{"issue":"9","key":"4519_CR19","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.1200\/OP.20.00619","volume":"17","author":"S Teckie","year":"2021","unstructured":"Teckie S, Makker V, Tabar V, et al. Impact of the COVID-19 pandemic surge on radiation treatment: report from a multicenter New York Area Institution. JCO Oncol Pract. 2021;17(9):e1245\u201351.","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"4519_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(20)30743-9","volume":"22","author":"K Spencer","year":"2021","unstructured":"Spencer K, Morris E, Dugdale E, et al. Impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021;22(4):491\u2013500.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4519_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12094-018-1943-z","volume":"21","author":"JL L\u00f3pez Torrecilla","year":"2019","unstructured":"Torrecilla JL, Bayo E, Antol\u00edn E, et al. Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology. Clin Transl Oncol. 2018;20(9):1161\u201370.","journal-title":"Clin Transl Oncol"},{"issue":"18","key":"4519_CR22","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","volume":"28","author":"LJ Peters","year":"2010","unstructured":"Peters LJ, O\u2019Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996\u20133001.","journal-title":"J Clin Oncol"},{"issue":"24","key":"4519_CR23","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595\u2013603.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4519_CR24","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326\u201347.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4519_CR25","doi-asserted-by":"publisher","first-page":"101784","DOI":"10.1016\/j.adro.2025.101784","volume":"10","author":"J Yin","year":"2025","unstructured":"Yin J, Huang D, Hirsch AE, et al. Factors associated with early discontinuation of radiation therapy: an analysis of the National Cancer Database. Adv Radiat Oncol. 2025;10(4):101784.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"4519_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.adro.2017.10.006","volume":"3","author":"S Lazarev","year":"2017","unstructured":"Lazarev S, Gupta V, Ghiassi-Nejad Z, et al. Premature discontinuation of curative radiation therapy: insights from head and neck irradiation. Adv Radiat Oncol. 2018;3(1):62\u20139.","journal-title":"Adv Radiat Oncol"},{"issue":"35","key":"4519_CR27","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","volume":"25","author":"TK Owonikoko","year":"2007","unstructured":"Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25(35):5570\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4519_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187\u201393.","journal-title":"J Clin Oncol"},{"key":"4519_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.radonc.2022.01.030","volume":"168","author":"JH Kutzko","year":"2022","unstructured":"Kutzko JH, Dadwal P, Holt T, et al. Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: a meta-analysis. Radiother Oncol. 2022;169:13\u201322. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.030.","journal-title":"Radiother Oncol"},{"issue":"3","key":"4519_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253\u201362.","journal-title":"Radiother Oncol"},{"key":"4519_CR31","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, King WD, Thibault I, et al. Pan-Canadian measurement of adherence to radiotherapy guideline wait times for curative treatment. Int J Radiat Oncol Biol Phys. 2016;95(5):1496\u2013504.","journal-title":"BMJ"},{"issue":"1","key":"4519_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0360-3016(95)02049-7","volume":"34","author":"WJ Mackillop","year":"1996","unstructured":"Mackillop WJ, Bates JH, O\u2019Sullivan B, et al. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34(1):243\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4519_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/cancers17010086","volume":"17","author":"AE Guerini","year":"2024","unstructured":"Guerini AE, Borghetti P, Filippi AR, et al. Multicentric analysis of the impact of COVID-19 on patients receiving anticancer treatment in Italy. Cancers (Basel). 2021;13(4):817.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4519_CR34","doi-asserted-by":"publisher","first-page":"mzab088","DOI":"10.1093\/intqhc\/mzab088","volume":"33","author":"M Powis","year":"2021","unstructured":"Saldanha EF, Nguyen J, Ballas LK, et al. Impact of the early phase of the COVID-19 pandemic on cancer treatment delivery. JCO Glob Oncol. 2021;7:97\u2013105.","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"4519_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cncr.28408","volume":"120","author":"MS Krishnan","year":"2014","unstructured":"Krishnan MS, Epstein-Peterson Z, Chen YH, et al. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer. 2014;120(1):134\u201341.","journal-title":"Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04519-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04519-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:18:08Z","timestamp":1787224688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04519-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":35,"alternative-id":["4519"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04519-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflict of interest. No funding was received for this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a retrospective institutional audit using anonymized clinical data. As a non-interventional analysis for quality assurance purposes, formal ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a retrospective institutional audit using anonymized clinical data. As a non-interventional analysis for quality assurance purposes, informed consent was not required.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}